News Archives - PsychoGenics

AI-discovered drug shows ‘enormous potential’ to treat schizophrenia: ‘Real need for better treatment’

by Eric | May 10, 2023

AI-discovered drug shows ‘enormous potential’ to treat schizophrenia: ‘Real need for better treatment’ May 9, 2023・By Angelica Stabile・Fox News PsychoGenics CEO reveals how machine learning has enabled new steps toward addressing mental disorder As...

PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery

by Eric | Apr 6, 2023

PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery April 6, 2023・Businesswire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO...

PsychoGenics highlights a long-term collaboration with the TSC Alliance on Rare Disease Day

by Eric | Feb 28, 2023

PsychoGenics highlights a long-term collaboration with the TSC Alliance on Rare Disease Day Feb. 28, 2023 On this Rare Disease Day, we want to highlight and honor our long-term collaboration with the TSC Alliance® in support of critical research for tuberous sclerosis...

PsychoGenics CEO explores CNS drug development trends

by Eric | Feb 4, 2023

PsychoGenics CEO explores CNS drug development trends February 4, 2023 · By Brian Buntz · Drug Discovery & Development In the late 2000s, many companies, particularly Big Pharma, exited the field of central nervous system (CNS) drug development and, particularly...

Why the TAAR1 agonist ulotaront holds promise for schizophrenia

by Eric | Nov 22, 2022

Why the TAAR1 agonist ulotaront holds promise for schizophrenia November 22, 2022 · By Brian Buntz · Drug Discovery & Development Ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist in Phase 3 clinical development, could prove to be a...

« Older Entries

AI-discovered drug shows ‘enormous potential’ to treat schizophrenia: ‘Real need for better treatment’

PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery

PsychoGenics highlights a long-term collaboration with the TSC Alliance on Rare Disease Day

PsychoGenics CEO explores CNS drug development trends

Why the TAAR1 agonist ulotaront holds promise for schizophrenia

Recent Comments

CONTACT